| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1027485871 |
| P356 | DOI | 10.1186/1465-9921-14-86 |
| P932 | PMC publication ID | 3765544 |
| P698 | PubMed publication ID | 23964926 |
| P5875 | ResearchGate publication ID | 256075518 |
| P2093 | author name string | Dong Soon Kim | |
| P2860 | cites work | Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3 | Q24624887 |
| Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis | Q24645989 | ||
| Classification and natural history of the idiopathic interstitial pneumonias | Q24655062 | ||
| Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures | Q26995277 | ||
| Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature | Q27004290 | ||
| Viruses as co-factors for the initiation or exacerbation of lung fibrosis | Q27487313 | ||
| BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy | Q27650860 | ||
| Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias | Q28143296 | ||
| Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials | Q28237583 | ||
| Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial | Q28250518 | ||
| A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis | Q28266119 | ||
| Pirfenidone in idiopathic pulmonary fibrosis | Q28267108 | ||
| An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management | Q28308246 | ||
| Circulating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis | Q61892487 | ||
| CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis | Q71928966 | ||
| Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients | Q72196675 | ||
| Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis | Q79250523 | ||
| Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias | Q79667658 | ||
| Acute exacerbation of idiopathic pulmonary fibrosis | Q81589987 | ||
| Elevated Levels of Thioredoxin 1 in the Lungs and Sera of Idiopathic Pulmonary Fibrosis, Non-Specific Interstitial Pneumonia and Cryptogenic Organizing Pneumonia | Q82508181 | ||
| Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses | Q82750628 | ||
| Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis | Q83378832 | ||
| Acute exacerbation of idiopathic pulmonary fibrosis | Q83512453 | ||
| BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis | Q28308276 | ||
| Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials | Q30412203 | ||
| Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease | Q30442380 | ||
| The clinical course of patients with idiopathic pulmonary fibrosis | Q33987940 | ||
| Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis | Q33994636 | ||
| Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis | Q34223462 | ||
| Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis | Q34275871 | ||
| Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis | Q34554406 | ||
| TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease | Q34581113 | ||
| A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis | Q34619709 | ||
| Gradual increase of high mobility group protein b1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis | Q35001179 | ||
| Viral infection in acute exacerbation of idiopathic pulmonary fibrosis | Q35107245 | ||
| Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis | Q35535282 | ||
| Acute exacerbation of idiopathic pulmonary fibrosis: report of a series | Q35585584 | ||
| Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis | Q35683001 | ||
| Acute exacerbations of idiopathic pulmonary fibrosis | Q36168860 | ||
| Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series | Q36421434 | ||
| The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis | Q36803302 | ||
| Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review | Q37159799 | ||
| Does chronic microaspiration cause idiopathic pulmonary fibrosis? | Q37723619 | ||
| Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome | Q37769355 | ||
| Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors | Q37921059 | ||
| Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease | Q40388478 | ||
| Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases | Q40716833 | ||
| Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis | Q41137847 | ||
| Long-Term Efficacy of Inhaled N-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis | Q42837430 | ||
| Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis | Q43194065 | ||
| Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results | Q43223134 | ||
| Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. | Q44233204 | ||
| Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. | Q44524980 | ||
| Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. | Q45022379 | ||
| Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. | Q45991541 | ||
| Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis | Q46135485 | ||
| Anticoagulant therapy for idiopathic pulmonary fibrosis | Q46703272 | ||
| Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. | Q46917886 | ||
| Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study | Q47897193 | ||
| Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis | Q48001425 | ||
| Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. | Q50853560 | ||
| Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. | Q53557884 | ||
| Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. | Q54323420 | ||
| Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study | Q57762802 | ||
| Histopathologic Features and Outcome of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis Undergoing Surgical Lung Biopsy | Q58002473 | ||
| P921 | main subject | pulmonary fibrosis | Q32446 |
| P304 | page(s) | 86 | |
| P577 | publication date | 2013-08-21 | |
| P1433 | published in | Respiratory Research | Q7315904 |
| P1476 | title | Acute exacerbations in patients with idiopathic pulmonary fibrosis | |
| P478 | volume | 14 |
| Q37421028 | Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway |
| Q41812311 | Bone marrow mesenchymal stem cells protect against bleomycin-induced pulmonary fibrosis in rat by activating Nrf2 signaling. |
| Q60912486 | Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data |
| Q38288028 | Diagnosis and management of interstitial lung disease |
| Q92660539 | Gastric Acid and Pepsin Work Together in Simulated Gastric Acid Inhalation Leading to Pulmonary Fibrosis in Rats |
| Q34973462 | Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis |
| Q28079373 | Mesenchymal stem cells in the treatment of chronic lung disease |
| Q26783169 | Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis |
| Q43184339 | Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases |
| Q38718875 | Therapeutic advances in idiopathic pulmonary fibrosis |
| Q41712176 | Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries |
Search more.